In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

SINCE the first edition of this great work was reviewed in these pages (NATURE, vol. iii., pp. 442, 463), it has been repeatedly reprinted without any important change. But the new issue differs, not ...